Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis

被引:0
作者
Nathalie LeVasseur
J. Sun
L. Gondara
R. Diocee
C. Speers
C. Lohrisch
S. Chia
机构
[1] BC Cancer-Vancouver Centre,Department of Medical Oncology
[2] British Columbia Cancer Agency,Breast Cancer Outcomes Unit
来源
Journal of Cancer Research and Clinical Oncology | 2020年 / 146卷
关键词
Neoadjuvant; Pathologic complete response; Residual disease; Pre-operative treatment;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:529 / 536
页数:7
相关论文
共 119 条
[1]  
Bear HD(2003)The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J Clin Oncol 21 4165-4174
[2]  
Anderson S(2014)Pathologic complete response as a potential surrogate for the clinical outcome in patients with breast cancer after neoadjuvant therapy: a meta-regression of 29 randomized prospective studies J Clin Oncol 32 3883-3891
[3]  
Brown A(2016)Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis JAMA Oncol. 2 751-760
[4]  
Smith R(2014)Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis Lancet 384 164-172
[5]  
Mamounas EP(2005)Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer—a study from the IMPACT trialists J Clin Oncol 23 2477-2492
[6]  
Fisher B(1997)Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18 J Clin Oncol 15 2483-2493
[7]  
Berruti A(2012)Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial Lancet Oncol. 13 25-32
[8]  
Amoroso V(2016)5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial Lancet Oncol. 17 791-800
[9]  
Gallo F(2012)Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy Eur J Cancer 48 3342-3354
[10]  
Bertaglia V(2017)Adjuvant capecitabine for breast cancer after preoperative chemotherapy N Engl J Med 376 2147-2159